Bilal A. Siddiqui

2.7k total citations · 2 hit papers
48 papers, 1.7k citations indexed

About

Bilal A. Siddiqui is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Bilal A. Siddiqui has authored 48 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 8 papers in Immunology. Recurrent topics in Bilal A. Siddiqui's work include Cancer Immunotherapy and Biomarkers (20 papers), Prostate Cancer Treatment and Research (17 papers) and Radiopharmaceutical Chemistry and Applications (6 papers). Bilal A. Siddiqui is often cited by papers focused on Cancer Immunotherapy and Biomarkers (20 papers), Prostate Cancer Treatment and Research (17 papers) and Radiopharmaceutical Chemistry and Applications (6 papers). Bilal A. Siddiqui collaborates with scholars based in United States, Australia and Netherlands. Bilal A. Siddiqui's co-authors include Sumit K. Subudhi, Padmanee Sharma, James P. Allison, Sangeeta Goswami, Swetha Anandhan, Shalini S. Yadav, Jianjun Gao, Deblina Raychaudhuri, Jielin Liu and Shelley M. Herbrich and has published in prestigious journals such as Cell, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Bilal A. Siddiqui

38 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Immune checkpoint therapy—current perspectives and future directions

2023 579 citations Padmanee Sharma, Sangeeta Goswami et al. profile →
The Next Decade of Immune Checkpoint Therapy

2021 480 citations Padmanee Sharma, Bilal A. Siddiqui et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bilal A. Siddiqui United States	11	824	802	440	233	183	48	1.7k
Heidi Harjunpää Finland	14	1.3k 1.5×	934 1.2×	458 1.0×	393 1.7×	83 0.5×	20	2.1k
Thomas U. Marron United States	17	520 0.6×	766 1.0×	337 0.8×	146 0.6×	96 0.5×	87	1.4k
Carl J. DeSelm United States	16	836 1.0×	468 0.6×	630 1.4×	189 0.8×	105 0.6×	34	1.7k
Lucas A. Horn United States	20	1.0k 1.2×	1.2k 1.5×	462 1.1×	216 0.9×	60 0.3×	27	1.9k
Jai Rautela Australia	19	1.0k 1.3×	1.3k 1.6×	648 1.5×	136 0.6×	74 0.4×	31	2.1k
Cristina Puig-Saus United States	13	1.4k 1.7×	1.0k 1.3×	704 1.6×	247 1.1×	81 0.4×	18	2.0k
Martin Holcmann Austria	17	508 0.6×	738 0.9×	476 1.1×	131 0.6×	80 0.4×	27	1.6k
Wendy K. Nevala United States	23	705 0.9×	810 1.0×	624 1.4×	168 0.7×	63 0.3×	67	1.8k
Tomohide Tsukahara Japan	29	1.2k 1.5×	1.0k 1.3×	982 2.2×	458 2.0×	130 0.7×	118	2.4k

Countries citing papers authored by Bilal A. Siddiqui

Since Specialization

Citations

This map shows the geographic impact of Bilal A. Siddiqui's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bilal A. Siddiqui with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bilal A. Siddiqui more than expected).

Fields of papers citing papers by Bilal A. Siddiqui

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bilal A. Siddiqui. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bilal A. Siddiqui. The network helps show where Bilal A. Siddiqui may publish in the future.

Co-authorship network of co-authors of Bilal A. Siddiqui

This figure shows the co-authorship network connecting the top 25 collaborators of Bilal A. Siddiqui. A scholar is included among the top collaborators of Bilal A. Siddiqui based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bilal A. Siddiqui. Bilal A. Siddiqui is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sherry, Alexander D., Cara Haymaker, Bryan Fellman, et al.. (2025). Metastasis-directed therapy (MDT) plus androgen deprivation therapy (ADT) for oligometastatic prostate cancer (omPC): Primary results of the EXTEND continuous ADT (cADT) basket plus combined analysis with the updated intermittent ADT (iADT) basket and immune correlatives.. Journal of Clinical Oncology. 43(5_suppl). 140–140. 1 indexed citations

Aggarwal, Rahul, Sylvie Rottey, Alice Bernard‐Tessier, et al.. (2025). Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study. Clinical Cancer Research. 31(18). 3854–3863.

Aggarwal, Rahul, Sylvie Rottey, Alice Bernard‐Tessier, et al.. (2025). Data from Safety and Efficacy of Tarlatamab in Patients with Neuroendocrine Prostate Cancer: Results from the Phase 1b DeLLpro-300 Study.

Kelly, William Kevin, Sandy Srinivas, Joseph Maly, et al.. (2025). Phase 1/2 study of REGN4336 alone or in combination with cemiplimab or nezastomig in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 43(5_suppl). 1 indexed citations

Lacourt, Tamara E., Marc C. Schubert, Bilal A. Siddiqui, Sumit K. Subudhi, & Deepti Chopra. (2025). Neuropsychiatric events following high-dose steroid administration during early immune checkpoint therapy are more frequent with extended steroid exposure. Supportive Care in Cancer. 33(12). 1031–1031.

Siddiqui, Bilal A., Nicolas L. Palaskas, Sreyashi Basu, et al.. (2024). Molecular Pathways and Cellular Subsets Associated with Adverse Clinical Outcomes in Overlapping Immune-Related Myocarditis and Myositis. Cancer Immunology Research. 12(8). 964–987. 7 indexed citations

Ali, Abdelrahman, Lu Yang, Shaden Khalaf, et al.. (2024). Use of positron emission tomography for the diagnosis of immune-checkpoint inhibitor| myocarditis. Journal of Nuclear Cardiology. 39. 101909–101909.

Tidwell, Rebecca S., Yao Yu, Amado J. Zurita, et al.. (2024). Body composition in recurrent prostate cancer and the role of steroidogenic genotype. Endocrine Related Cancer. 31(12).

Hahn, Andrew W., et al.. (2023). Cancer Cell–Extrinsic Roles for the Androgen Receptor in Prostate Cancer. Endocrinology. 164(6). 9 indexed citations

10.

Wang, Yinghong, Malek Shatila, Anusha Shirwaikar Thomas, et al.. (2023). Tu1734 RANDOMIZED CLINICAL TRIAL OF INFLIXIMAB VERSUS VEDOLIZUMAB FOR IMMUNE CHECKPOINT INHIBITOR RELATED COLITIS. Gastroenterology. 164(6). S–1101. 1 indexed citations

11.

Hahn, Andrew W., Rebecca S. Tidwell, Efstratios Koutroumpakis, et al.. (2023). A phase II trial modifying metabolic syndrome and cardiovascular risk for patients with prostate cancer on ADT using a risk factor modification program and continuous Fitbit monitoring (ProTrio).. Journal of Clinical Oncology. 41(6_suppl). TPS273–TPS273. 1 indexed citations

12.

Tidwell, Rebecca S., Miao Zhang, Keyi Zhu, et al.. (2023). Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments. Cancers. 15(24). 5843–5843. 2 indexed citations

13.

Liu, Cynthia, Dongfeng Tan, Mehmet Altan, et al.. (2022). Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to PD-1 and PD-L1 inhibitors. Journal of Cancer Research and Clinical Oncology. 149(8). 5429–5436. 2 indexed citations

14.

Goswami, Sangeeta, Bilal A. Siddiqui, Sumit K. Subudhi, et al.. (2022). A composite T cell biomarker in pre-treatment blood samples correlates with detection of immune-related adverse events. Cancer Cell. 40(3). 249–251. 6 indexed citations

15.

Siddiqui, Bilal A., Sumit K. Subudhi, & Padmanee Sharma. (2022). Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer. Cell Reports Medicine. 3(4). 100613–100613. 5 indexed citations

16.

Subudhi, Sumit K., Bilal A. Siddiqui, Ana M. Aparicio, et al.. (2021). Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. Journal for ImmunoTherapy of Cancer. 9(10). e002919–e002919. 41 indexed citations

17.

Sharma, Padmanee, Bilal A. Siddiqui, Swetha Anandhan, et al.. (2021). The Next Decade of Immune Checkpoint Therapy. Cancer Discovery. 11(4). 838–857. 480 indexed citations breakdown →

18.

Siddiqui, Bilal A., et al.. (2021). Paraneoplastic Cerebellar Degeneration (PCD) associated with PCA-1 antibodies in established cancer patients. Journal of Neuro-Oncology. 153(3). 441–446. 3 indexed citations

19.

Siddiqui, Bilal A., et al.. (2020). EXPAREL® (Long-Acting Liposomal Bupivacaine) Use for Popliteal Nerve Block in Postoperative Pain Control after Ankle Fracture Fixation. Pain Research and Management. 2020. 1–5. 6 indexed citations

20.

Msaouel, Pavlos, Clara Oromendia, Jianjun Gao, et al.. (2020). Technology-enabled longitudinal monitoring of patient-reported outcomes (PROs) to individualize care of immune-related adverse events (irAEs) in patients (pts) treated with immune checkpoint inhibitors (ICIs).. Journal of Clinical Oncology. 38(15_suppl). TPS2088–TPS2088. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact